Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions

Drug Resistance Updates

Volumn 24, Issue , 2016, Pages 55-69

  Alkema, Nicolette G ^a   Wisman, G Bea A ^a   Van Der Zee, Ate G J ^a   Van Vugt, Marcel A T M ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BRCA1; BRCA2; Chemotherapy; High grade serous ovarian cancer; p53; PARP inhibitors; Patient derived xenografts; Platinum; Resistance

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; PLATINUM; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; DNA REPAIR; EX VIVO STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETICALLY ENGINEERED MOUSE STRAIN; HIGH GRADE SEROUS OVARY CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; IN VIVO STUDY; NONHUMAN; OVARY CANCER; PETRI DISH; PRIMARY CELL LINE; PRIORITY JOURNAL; TISSUE SLICE; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; CANCER GRADING; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; THEORETICAL MODEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MODELS, THEORETICAL; NEOPLASM GRADING; OVARIAN NEOPLASMS; PLATINUM; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 84950252556     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2015.11.005     Document Type: Article

References (195)

1. S. Aebi, M. Castiglione, and E.G.W. Group Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann. Oncol. 19 Suppl. 2 2008 ii14 ii16 (Official Journal of the European Society for Medical Oncology/ESMO)
2. C. Alix-Panabieres, and K. Pantel Circulating tumor cells: liquid biopsy of cancer Clin. Chem. 59 2013 110 118
3. N.G. Alkema, T. Tomar, E.W. Duiker, G. Jan Meersma, H. Klip, A.G. van der Zee, G.B. Wisman, and S. de Jong Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods Sci. Rep. 5 2015 p14495
4. M.D. Amatangelo, A. Garipov, H. Li, J.R. Conejo-Garcia, D.W. Speicher, and R. Zhang Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition Cell Cycle 12 2013 2113 2119
5. M.S. Anglesio, K.C. Wiegand, N. Melnyk, C. Chow, C. Salamanca, L.M. Prentice, J. Senz, W. Yang, M.A. Spillman, D.R. Cochrane, K. Shumansky, S.P. Shah, S.E. Kalloger, and D.G. Huntsman Type-specific cell line models for type-specific ovarian cancer research PLoS ONE 8 2013 pe72162
6. C. Balch, T.H. Huang, R. Brown, and K.P. Nephew The epigenetics of ovarian cancer drug resistance and resensitization Am. J. Obst. Gynecol. 191 2004 1552 1572
7. R.L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, S. Narod, and B.Y. Karlan BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study Cancer Res. 60 2000 5329 5333
8. R.B. Bankert, S.V. Balu-Iyer, K. Odunsi, L.D. Shultz, R.J. Kelleher Jr., J.L. Barnas, M. Simpson-Abelson, R. Parsons, and S.J. Yokota Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis PLoS ONE 6 2011 pe24420
9. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, S. Kim, C.J. Wilson, J. Lehar, G.V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M.F. Berger, J.E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jane-Valbuena, F.A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I.H. Engels, J. Cheng, G.K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M.D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R.C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J.P. Mesirov, S.B. Gabriel, G. Getz, K. Ardlie, V. Chan, V.E. Myer, B.L. Weber, J. Porter, M. Warmuth, P. Finan, J.L. Harris, M. Meyerson, T.R. Golub, M.P. Morrissey, W.R. Sellers, R. Schlegel, and L.A. Garraway The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
10. A. Bashashati, G. Ha, A. Tone, J. Ding, L.M. Prentice, A. Roth, J. Rosner, K. Shumansky, S. Kalloger, J. Senz, W. Yang, M. McConechy, N. Melnyk, M. Anglesio, M.T. Luk, K. Tse, T. Zeng, R. Moore, Y. Zhao, M.A. Marra, B. Gilks, S. Yip, D.G. Huntsman, J.N. McAlpine, and S.P. Shah Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling J. Pathol. 231 2013 21 34
11. C.M. Beaufort, J.C. Helmijr, A.M. Piskorz, M. Hoogstraat, K. Ruigrok-Ritstier, N. Besselink, M. Murtaza, I.W.F. van, A.A. Heine, M. Smid, M.J. Koudijs, J.D. Brenton, E.M. Berns, and J. Helleman Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes PLoS ONE 9 2014 pe103988
12. D.P. Berger, H. Henss, B.R. Winterhalter, and H.H. Fiebig The clonogenic assay with human tumor xenografts: evaluation, predictive value and application for drug screening Ann. Oncol. 1 1990 333 341 (Official Journal of the European Society for Medical Oncology/ESMO)
13. E.M. Berns, and D.D. Bowtell The changing view of high-grade serous ovarian cancer Cancer Res. 72 2012 2701 2704
14. A. Bertotti, G. Migliardi, F. Galimi, F. Sassi, D. Torti, C. Isella, D. Cora, F. Di Nicolantonio, M. Buscarino, C. Petti, D. Ribero, N. Russolillo, A. Muratore, P. Massucco, A. Pisacane, L. Molinaro, E. Valtorta, A. Sartore-Bianchi, M. Risio, L. Capussotti, M. Gambacorta, S. Siena, E. Medico, A. Sapino, S. Marsoni, P.M. Comoglio, A. Bardelli, and L. Trusolino A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer Cancer Discov. 1 2011 508 523
15. B.G. Bitler, K.M. Aird, A. Garipov, H. Li, M. Amatangelo, A.V. Kossenkov, D.C. Schultz, Q. Liu, M. Shih Ie, J.R. Conejo-Garcia, D.W. Speicher, and R. Zhang Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers Nat. Med. 21 2015 231 238
16. G. Bolis, G. Scarfone, L. Luchini, C. Ferraris, F. Zanaboni, M. Presti, G. Giardina, A. Villa, and F. Parazzini Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated with a cisplatin- or carboplatin-based regimen Eur. J. Cancer 30A 1994 1764 1768
17. P. Bouwman, A. Aly, J.M. Escandell, M. Pieterse, J. Bartkova, H. van der Gulden, S. Hiddingh, M. Thanasoula, A. Kulkarni, Q. Yang, B.G. Haffty, J. Tommiska, C. Blomqvist, R. Drapkin, D.J. Adams, H. Nevanlinna, J. Bartek, M. Tarsounas, S. Ganesan, and J. Jonkers 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Nat. Struct. Mol. Biol. 17 2010 688 695
18. P. Bouwman, and J. Jonkers Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin. Cancer Res. 20 2014 540 547 (an official journal of the American Association for Cancer Research)
19. P. Bouwman, H. van der Gulden, I. van der Heijden, R. Drost, C.N. Klijn, P. Prasetyanti, M. Pieterse, E. Wientjens, J. Seibler, F.B. Hogervorst, and J. Jonkers A high-throughput functional complementation assay for classification of BRCA1 missense variants Cancer Discov. 3 2013 1142 1155
20. D.D. Bowtell, S. Bohm, A.A. Ahmed, P.J. Aspuria, R.C. Bast Jr., V. Beral, J.S. Berek, M.J. Birrer, S. Blagden, M.A. Bookman, J.D. Brenton, K.B. Chiappinelli, F.C. Martins, G. Coukos, R. Drapkin, R. Edmondson, C. Fotopoulou, H. Gabra, J. Galon, C. Gourley, V. Heong, D.G. Huntsman, M. Iwanicki, B.Y. Karlan, A. Kaye, E. Lengyel, D.A. Levine, K.H. Lu, I.A. McNeish, U. Menon, S.A. Narod, B.H. Nelson, K.P. Nephew, P. Pharoah, D.J. Powell Jr., P. Ramos, I.L. Romero, C.L. Scott, A.K. Sood, E.A. Stronach, and F.R. Balkwill Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer Nat. Rev. Cancer 15 2015 668 679
21. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, H.C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T.M. Salay, S. Alaparthy, J.F. Grosso, A.J. Korman, S.M. Parker, S. Agrawal, S.M. Goldberg, D.M. Pardoll, A. Gupta, and J.M. Wigginton Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Eng. J. Med. 366 2012 2455 2465
22. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J. Clin. Oncol. 20 2002 1248 1259 (Official Journal of the American Society of Clinical Oncology)
23. R. Brown, E. Curry, L. Magnani, C.S. Wilhelm-Benartzi, and J. Borley Poised epigenetic states and acquired drug resistance in cancer Nat. Rev. Cancer 14 2014 747 753
24. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, S. Kyle, M. Meuth, N.J. Curtin, and T. Helleday Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
25. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
26. J.W. Cassidy, C. Caldas, and A. Bruna Maintaining tumor heterogeneity in patient-derived tumor xenografts Cancer Res. 75 2015 2963 2968
27. M. Castells, D. Milhas, C. Gandy, B. Thibault, A. Rafii, J.P. Delord, and B. Couderc Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation Cell Death Dis. 4 2013 pe887
28. M. Castells, B. Thibault, J.P. Delord, and B. Couderc Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death Int. J. Mol. Sci. 13 2012 9545 9571
29. A. Catteau, W.H. Harris, C.F. Xu, and E. Solomon Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics Oncogene 18 1999 1957 1965
30. K.Y. Chan, H. Ozcelik, A.N. Cheung, H.Y. Ngan, and U.S. Khoo Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer Cancer Res. 62 2002 4151 4156
31. P. Chaudhry, R. Srinivasan, and F.D. Patel Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC) Cancer Investig. 27 2009 877 884
32. A.A. Chekmasova, and R.J. Brentjens Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer Discov. Med. 9 2010 62 70
33. J. Chen, J. Wang, Y. Zhang, D. Chen, C. Yang, C. Kai, X. Wang, F. Shi, and J. Dou Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture J. Biosci. Bioeng. 118 2014 214 222
34. P. Chen, K. Huhtinen, K. Kaipio, P. Mikkonen, V. Aittomaki, R. Lindell, J. Hynninen, A. Auranen, S. Grenman, R. Lehtonen, O. Carpen, and S. Hautaniemi Identification of prognostic groups in high-grade serous ovarian cancer treated with platinum-taxane chemotherapy Cancer Res. 75 2015 2987 2998
35. X.X. Chen, F.F. Xie, X.J. Zhu, F. Lin, S.S. Pan, L.H. Gong, J.G. Qiu, W.J. Zhang, Q.W. Jiang, X.L. Mei, Y.Q. Xue, W.M. Qin, Z. Shi, and X.J. Yan Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer Oncotarget 6 2015 14926 14939
36. Z. Chen, K. Cheng, Z. Walton, Y. Wang, H. Ebi, T. Shimamura, Y. Liu, T. Tupper, J. Ouyang, J. Li, P. Gao, M.S. Woo, C. Xu, M. Yanagita, A. Altabef, S. Wang, C. Lee, Y. Nakada, C.G. Pena, Y. Sun, Y. Franchetti, C. Yao, A. Saur, M.D. Cameron, M. Nishino, D.N. Hayes, M.D. Wilkerson, P.J. Roberts, C.B. Lee, N. Bardeesy, M. Butaney, L.R. Chirieac, D.B. Costa, D. Jackman, N.E. Sharpless, D.H. Castrillon, G.D. Demetri, P.A. Janne, P.P. Pandolfi, L.C. Cantley, A.L. Kung, J.A. Engelman, and K.K. Wong A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response Nature 483 2012 613 617
37. M. Chimonidou, A. Strati, A. Tzitzira, G. Sotiropoulou, N. Malamos, V. Georgoulias, and E.S. Lianidou DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells Clin. Chem. 57 2011 1169 1177
38. K.V. Clark-Knowles, M.K. Senterman, O. Collins, and B.C. Vanderhyden Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas PLoS ONE 4 2009 pe8534
39. P.E. Colombo, S. du Manoir, B. Orsett, R. Bras-Goncalves, M.B. Lambros, A. MacKay, T.T. Nguyen, F. Boissiere, D. Pourquier, F. Bibeau, J.S. Reis-Filho, and C. Theillet Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure Oncotarget 6 2015 28327 28340
40. S.L. Cooke, and J.D. Brenton Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol. 12 2011 1169 1174
41. S.L. Cooke, C.K. Ng, N. Melnyk, M.J. Garcia, T. Hardcastle, J. Temple, S. Langdon, D. Huntsman, and J.D. Brenton Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma Oncogene 29 2010 4905 4913
42. A.P. Crijns, R.S. Fehrmann, S. de Jong, F. Gerbens, G.J. Meersma, H.G. Klip, H. Hollema, R.M. Hofstra, G.J. te Meerman, E.G. de Vries, and A.G. van der Zee Survival-related profile, pathways, and transcription factors in ovarian cancer PLoS Med. 6 2009 pe24
43. M. Cristofanilli, D.F. Hayes, G.T. Budd, M.J. Ellis, A. Stopeck, J.M. Reuben, G.V. Doyle, J. Matera, W.J. Allard, M.C. Miller, H.A. Fritsche, G.N. Hortobagyi, and L.W. Terstappen Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer J. Clin. Oncol. 23 2005 1420 1430 (official journal of the American Society of Clinical Oncology)
44. D.C. Danila, G. Heller, G.A. Gignac, R. Gonzalez-Espinoza, A. Anand, E. Tanaka, H. Lilja, L. Schwartz, S. Larson, M. Fleisher, and H.I. Scher Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer Clin. Cancer Res. 13 2007 7053 7058 (An Official Journal of the American Association for Cancer Research)
45. M. Das Thakur, N.K. Pryer, and M. Singh Mouse tumour models to guide drug development and identify resistance mechanisms J. Pathol. 232 2014 103 111
46. M. Das Thakur, F. Salangsang, A.S. Landman, W.R. Sellers, N.K. Pryer, M.P. Levesque, R. Dummer, M. McMahon, and D.D. Stuart Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
47. K. Do, D. Wilsker, J. Ji, J. Zlott, T. Freshwater, R.J. Kinders, J. Collins, A.P. Chen, J.H. Doroshow, and S. Kummar Phase I study of single-agent AZD1775 (MK-1775), a wee1 kinase inhibitor, in patients with refractory solid tumors J. Clin. Oncol. 33 2015 3409 3415 (Official Journal of the American Society of Clinical Oncology)
48. Z.C. Dobbin, A.A. Katre, A.D. Steg, B.K. Erickson, M.M. Shah, R.D. Alvarez, M.G. Conner, D. Schneider, D. Chen, and C.N. Landen Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer Oncotarget 5 2014 8750 8764
49. S. Domcke, R. Sinha, D.A. Levine, C. Sander, and N. Schultz Evaluating cell lines as tumour models by comparison of genomic profiles Nat. Commun. 4 2013 p2126
50. H.K. Dressman, A. Berchuck, G. Chan, J. Zhai, A. Bild, R. Sayer, J. Cragun, J. Clarke, R.S. Whitaker, L. Li, J. Gray, J. Marks, G.S. Ginsburg, A. Potti, M. West, J.R. Nevins, and J.M. Lancaster An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer J. Clin. Oncol. 25 2007 517 525 (Official Journal of the American Society of Clinical Oncology)
51. R. Drost, P. Bouwman, S. Rottenberg, U. Boon, E. Schut, S. Klarenbeek, C. Klijn, I. van der Heijden, H. van der Gulden, E. Wientjens, M. Pieterse, A. Catteau, P. Green, E. Solomon, J.R. Morris, and J. Jonkers BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance Cancer Cell 20 2011 797 809
52. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schroder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, J. Pfisterer, G. Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1329
53. S.L. Edwards, R. Brough, C.J. Lord, R. Natrajan, R. Vatcheva, D.A. Levine, J. Boyd, J.S. Reis-Filho, and A. Ashworth Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 2008 1111 1115
54. B.O. Einarsdottir, R.O. Bagge, J. Bhadury, H. Jespersen, J. Mattsson, L.M. Nilsson, K. Truve, M.D. Lopez, P. Naredi, O. Nilsson, U. Stierner, L. Ny, and J.A. Nilsson Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions Oncotarget 5 2014 9609 9618
55. P. Eirew, A. Steif, J. Khattra, G. Ha, D. Yap, H. Farahani, K. Gelmon, S. Chia, C. Mar, A. Wan, E. Laks, J. Biele, K. Shumansky, J. Rosner, A. McPherson, C. Nielsen, A.J. Roth, C. Lefebvre, A. Bashashati, C. de Souza, C. Siu, R. Aniba, J. Brimhall, A. Oloumi, T. Osako, A. Bruna, J.L. Sandoval, T. Algara, W. Greenwood, K. Leung, H. Cheng, H. Xue, Y. Wang, D. Lin, A.J. Mungall, R. Moore, Y. Zhao, J. Lorette, L. Nguyen, D. Huntsman, C.J. Eaves, C. Hansen, M.A. Marra, C. Caldas, S.P. Shah, and S. Aparicio Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution Nature 518 2015 422 426
56. M. Esteller, J.M. Silva, G. Dominguez, F. Bonilla, X. Matias-Guiu, E. Lerma, E. Bussaglia, J. Prat, I.C. Harkes, E.A. Repasky, E. Gabrielson, M. Schutte, S.B. Baylin, and J.G. Herman Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors J. Natl. Cancer Inst. 92 2000 564 569
57. J.M. Estes, P.G. Oliver, J.M. Straughn Jr., T. Zhou, W. Wang, W.E. Grizzle, R.D. Alvarez, C.R. Stockard, A.F. LoBuglio, and D.J. Buchsbaum Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model Gynecol. Oncol. 105 2007 291 298
58. D. Etemadmoghadam, A. deFazio, R. Beroukhim, C. Mermel, J. George, G. Getz, R. Tothill, A. Okamoto, M.B. Raeder, P. Harnett, S. Lade, L.A. Akslen, A.V. Tinker, B. Locandro, K. Alsop, Y.E. Chiew, N. Traficante, S. Fereday, D. Johnson, S. Fox, W. Sellers, M. Urashima, H.B. Salvesen, M. Meyerson, D. Bowtell, and A.S. Group Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas Clin. Cancer Res. 15 2009 1417 1427 (An Official Journal of the American Association for Cancer Research)
59. T. Fan, Q. Zhao, J.J. Chen, W.T. Chen, and M.L. Pearl Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer Gynecol. Oncol. 112 2009 185 191
60. F. Fang, C. Balch, J. Schilder, T. Breen, S. Zhang, C. Shen, L. Li, C. Kulesavage, A.J. Snyder, K.P. Nephew, and D.E. Matei A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer Cancer 116 2010 4043 4053
61. F. Fang, J. Munck, J. Tang, P. Taverna, Y. Wang, D.F. Miller, J. Pilrose, G. Choy, M. Azab, K.S. Pawelczak, P. VanderVere-Carozza, M. Wagner, J. Lyons, D. Matei, J.J. Turchi, and K.P. Nephew The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer Clin. Cancer Res. 20 2014 6504 6516 (An Official Journal of the American Association for Cancer Research)
62. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, N.M. Martin, S.P. Jackson, G.C. Smith, and A. Ashworth Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
63. R.S. Fehrmann, J.M. Karjalainen, M. Krajewska, H.J. Westra, D. Maloney, A. Simeonov, T.H. Pers, J.N. Hirschhorn, R.C. Jansen, E.A. Schultes, H.H. van Haagen, E.G. de Vries, G.J. Te Meerman, C. Wijmenga, M.A. van Vugt, and L. Franke Gene expression analysis identifies global gene dosage sensitivity in cancer Nat. Genet. 47 2015 115 125
64. R.S. Fehrmann, X.Y. Li, A.G. van der Zee, S. de Jong, G.J. Te Meerman, E.G. de Vries, and A.P. Crijns Profiling studies in ovarian cancer: a review Oncologist 12 2007 960 966
65. L. Feng, K.W. Fong, J. Wang, W. Wang, and J. Chen RIF1 counteracts BRCA1-mediated end resection during DNA repair J. Biol. Chem. 288 2013 11135 11143
66. H.H. Fiebig, A. Maier, and A.M. Burger Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery Eur. J. Cancer 40 2004 802 820
67. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, M. Mergui-Roelvink, P. Mortimer, H. Swaisland, A. Lau, M.J. O'Connor, A. Ashworth, J. Carmichael, S.B. Kaye, J.H. Schellens, and J.S. de Bono Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N. Eng. J. Med. 361 2009 123 134
68. P.J. Frederick, J.E. Kendrick, J.M. Straughn Jr., D.L. Della Manna, P.G. Oliver, H.Y. Lin, W.E. Grizzle, C.R. Stockard, R.D. Alvarez, T. Zhou, A.F. LoBuglio, and D.J. Buchsbaum Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model Int. J. Gynecol. Cancer 19 2009 814 819 (Official Journal of the International Gynecological Cancer Society)
69. E.S. Fuller, and V.M. Howell Culture models to define key mediators of cancer matrix remodeling Front. Oncol. 4 2014 p57
70. H. Gallion, W.A. Christopherson, R.L. Coleman, L. DeMars, T. Herzog, S. Hosford, H. Schellhas, A. Wells, and B.U. Sevin Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay Int. J. Gynecol. Cancer 16 2006 194 201 (Official Journal of the International Gynecological Cancer Society)
71. L. Galluzzi, L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, M. Castedo, and G. Kroemer Molecular mechanisms of cisplatin resistance Oncogene 31 2012 1869 1883
72. L. Galluzzi, I. Vitale, J. Michels, C. Brenner, G. Szabadkai, A. Harel-Bellan, M. Castedo, and G. Kroemer Systems biology of cisplatin resistance: past, present and future Cell Death Dis. 5 2014 pe1257
73. H. Gao, J.M. Korn, S. Ferretti, J.E. Monahan, Y. Wang, M. Singh, C. Zhang, C. Schnell, G. Yang, Y. Zhang, O.A. Balbin, S. Barbe, H. Cai, F. Casey, S. Chatterjee, D.Y. Chiang, S. Chuai, S.M. Cogan, S.D. Collins, E. Dammassa, N. Ebel, M. Embry, J. Green, A. Kauffmann, C. Kowal, R.J. Leary, J. Lehar, Y. Liang, A. Loo, E. Lorenzana, E. Robert McDonald.3rd., M.E. McLaughlin, J. Merkin, R. Meyer, T.L. Naylor, M. Patawaran, A. Reddy, C. Roelli, D.A. Ruddy, F. Salangsang, F. Santacroce, A.P. Singh, Y. Tang, W. Tinetto, S. Tobler, R. Velazquez, K. Venkatesan, F. Von Arx, H.Q. Wang, Z. Wang, M. Wiesmann, D. Wyss, F. Xu, H. Bitter, P. Atadja, E. Lees, F. Hofmann, E. Li, N. Keen, R. Cozens, M.R. Jensen, N.K. Pryer, J.A. Williams, and W.R. Sellers High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response Nat. Med. 21 2015 1318 1325
74. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, K.W. Lau, P. Greninger, I.R. Thompson, X. Luo, J. Soares, Q. Liu, F. Iorio, D. Surdez, L. Chen, R.J. Milano, G.R. Bignell, A.T. Tam, H. Davies, J.A. Stevenson, S. Barthorpe, S.R. Lutz, F. Kogera, K. Lawrence, A. McLaren-Douglas, X. Mitropoulos, T. Mironenko, H. Thi, L. Richardson, W. Zhou, F. Jewitt, T. Zhang, P. O'Brien, J.L. Boisvert, S. Price, W. Hur, W. Yang, X. Deng, A. Butler, H.G. Choi, J.W. Chang, J. Baselga, I. Stamenkovic, J.A. Engelman, S.V. Sharma, O. Delattre, J. Saez-Rodriguez, N.S. Gray, J. Settleman, P.A. Futreal, D.A. Haber, M.R. Stratton, S. Ramaswamy, U. McDermott, and C.H. Benes Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
75. E. Garralda, K. Paz, P.P. Lopez-Casas, S. Jones, A. Katz, L.M. Kann, F. Lopez-Rios, F. Sarno, F. Al-Shahrour, D. Vasquez, E. Bruckheimer, S.V. Angiuoli, A. Calles, L.A. Diaz, V.E. Velculescu, A. Valencia, D. Sidransky, and M. Hidalgo Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment Clin. Cancer Res. 20 2014 2476 2484 (An Official Journal of the American Association for Cancer Research)
76. K. Garson, L.F. Gamwell, E.M. Pitre, and B.C. Vanderhyden Technical challenges and limitations of current mouse models of ovarian cancer J. Ovarian Res. 5 2012 p39
77. K.A. Gelmon, M. Tischkowitz, H. Mackay, K. Swenerton, A. Robidoux, K. Tonkin, H. Hirte, D. Huntsman, M. Clemons, B. Gilks, R. Yerushalmi, E. Macpherson, J. Carmichael, and A. Oza Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study Lancet Oncol. 12 2011 852 861
78. M. Gerlinger, and C. Swanton How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine Br. J. Cancer 103 2010 1139 1143
79. P. Giannakakou, G. Poy, Z. Zhan, T. Knutsen, M.V. Blagosklonny, and T. Fojo Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer Oncogene 19 2000 3078 3085
80. G. Gifford, J. Paul, P.A. Vasey, S.B. Kaye, and R. Brown The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients Clin. Cancer Res. 10 2004 4420 4426 (An Official Journal of the American Association for Cancer Research)
81. R.M. Glasspool, R. Brown, M.E. Gore, G.J. Rustin, I.A. McNeish, R.H. Wilson, S. Pledge, J. Paul, M. Mackean, G.D. Hall, H. Gabra, S.E. Halford, J. Walker, K. Appleton, R. Ullah, S. Kaye Scottish Gynaecological Trials Group A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer Br. J. Cancer 110 2014 1923 1929
82. A.K. Godwin, A. Meister, P.J. O'Dwyer, C.S. Huang, T.C. Hamilton, and M.E. Anderson High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc. Natl. Acad. Sci. U.S.A. 89 1992 3070 3074
83. M.E. Gore, I. Fryatt, E. Wiltshaw, and T. Dawson Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecol. Oncol. 36 1990 207 211
84. G.S. Herter-Sprie, A.L. Kung, and K.K. Wong New cast for a new era: preclinical cancer drug development revisited J. Clin. Investig. 123 2013 3639 3645
85. T.J. Herzog, T.C. Krivak, A.N. Fader, and R.L. Coleman Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer Am. J. Obst. Gynecol. 203 2010 68.e61 68.e66
86. T.E. Hetland, J. Kaern, M. Skrede, B. Sandstad, C. Trope, B. Davidson, and V.A. Florenes Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index Cancer Chemother. Pharmacol. 69 2012 1307 1314
87. M. Hidalgo, F. Amant, A.V. Biankin, E. Budinska, A.T. Byrne, C. Caldas, R.B. Clarke, S. de Jong, J. Jonkers, G.M. Maelandsmo, S. Roman-Roman, J. Seoane, L. Trusolino, and A. Villanueva Patient-derived xenograft models: an emerging platform for translational cancer research Cancer Discov. 4 2014 998 1013
88. M. Hidalgo, E. Bruckheimer, N.V. Rajeshkumar, I. Garrido-Laguna, E. De Oliveira, B. Rubio-Viqueira, S. Strawn, M.J. Wick, J. Martell, and D. Sidransky A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer Mol. Cancer Ther. 10 2011 1311 1316
89. H. Hirai, Y. Iwasawa, M. Okada, T. Arai, T. Nishibata, M. Kobayashi, T. Kimura, N. Kaneko, J. Ohtani, K. Yamanaka, H. Itadani, I. Takahashi-Suzuki, K. Fukasawa, H. Oki, T. Nambu, J. Jiang, T. Sakai, H. Arakawa, T. Sakamoto, T. Sagara, T. Yoshizumi, S. Mizuarai, and H. Kotani Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Mol. Cancer Ther. 8 2009 2992 3000
90. C.L. Hodgkinson, C.J. Morrow, Y. Li, R.L. Metcalf, D.G. Rothwell, F. Trapani, R. Polanski, D.J. Burt, K.L. Simpson, K. Morris, S.D. Pepper, D. Nonaka, A. Greystoke, P. Kelly, B. Bola, M.G. Krebs, J. Antonello, M. Ayub, S. Faulkner, L. Priest, L. Carter, C. Tate, C.J. Miller, F. Blackhall, G. Brady, and C. Dive Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer Nat. Med. 20 2014 897 903
91. M. Hoogstraat, M.S. de Pagter, G.A. Cirkel, M.J. van Roosmalen, T.T. Harkins, K. Duran, J. Kreeftmeijer, I. Renkens, P.O. Witteveen, C.C. Lee, I.J. Nijman, T. Guy, R. van 't Slot, T.N. Jonges, M.P. Lolkema, M.J. Koudijs, R.P. Zweemer, E.E. Voest, E. Cuppen, and W.P. Kloosterman Genomic and transcriptomic plasticity in treatment-naive ovarian cancer Genome Res. 24 2014 200 211
92. C.D. House, L. Hernandez, and C.M. Annunziata Recent technological advances in using mouse models to study ovarian cancer Front. Oncol. 4 2014 p26
93. J.M. Houthuijzen, L.G. Daenen, J.M. Roodhart, and E.E. Voest The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression Br. J. Cancer 106 2012 1901 1906
94. J.M. Houthuijzen, L.G. Daenen, J.M. Roodhart, I. Oosterom, M.T. van Jaarsveld, K.M. Govaert, M.E. Smith, S.J. Sadatmand, H. Rosing, F. Kruse, B.J. Helms, N. van Rooijen, J.H. Beijnen, B. Haribabu, C.H. van de Lest, and E.E. Voest Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage response Nat. Comm. 5 2014 5275
95. C.J. Huntoon, K.S. Flatten, A.E. Wahner Hendrickson, A.M. Huehls, S.L. Sutor, S.H. Kaufmann, and L.M. Karnitz ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status Cancer Res. 73 2013 3683 3691
96. B.L. Hylander, N. Punt, H. Tang, J. Hillman, M. Vaughan, W. Bshara, R. Pitoniak, and E.A. Repasky Origin of the vasculature supporting growth of primary patient tumor xenografts J. Transl. Med. 11 2013 p110
97. T.A. Ince, A.D. Sousa, M.A. Jones, J.C. Harrell, E.S. Agoston, M. Krohn, L.M. Selfors, W. Liu, K. Chen, M. Yong, P. Buchwald, B. Wang, K.S. Hale, E. Cohick, P. Sergent, A. Witt, Z. Kozhekbaeva, S. Gao, A.T. Agoston, M.A. Merritt, R. Foster, B.R. Rueda, C.P. Crum, J.S. Brugge, and G.B. Mills Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours Nat. Commun. 6 2015 p7419
98. C. Isella, A. Terrasi, S.E. Bellomo, C. Petti, G. Galatola, A. Muratore, A. Mellano, R. Senetta, A. Cassenti, C. Sonetto, G. Inghirami, L. Trusolino, Z. Fekete, M. De Ridder, P. Cassoni, G. Storme, A. Bertotti, and E. Medico Stromal contribution to the colorectal cancer transcriptome Nat. Genet. 47 2015 312 319
99. H. Itamochi, J. Kigawa, and N. Terakawa Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma Cancer Sci. 99 2008 653 658
100. J.E. Jaspers, A. Kersbergen, U. Boon, W. Sol, L. van Deemter, S.A. Zander, R. Drost, E. Wientjens, J. Ji, A. Aly, J.H. Doroshow, A. Cranston, N.M. Martin, A. Lau, M.J. O'Connor, S. Ganesan, P. Borst, J. Jonkers, and S. Rottenberg Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors Cancer Discov. 3 2013 68 81
101. A.A. Jazaeri, J.L. Bryant, H. Park, H. Li, N. Dahiya, M.H. Stoler, J.S. Ferriss, and A. Dutta Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma Neoplasia 13 2011 899 911
102. O. Jonas, H.M. Landry, J.E. Fuller, J.T. Santini Jr., J. Baselga, R.I. Tepper, M.J. Cima, and R. Langer An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors Sci. Transl. Med. 7 2015 284ra257
103. P.M. Jones, and R. Drapkin Modeling high-grade serous carcinoma: how converging insights into pathogenesis and genetics are driving better experimental platforms Front. Oncol. 3 2013 217
104. A.M. Karst, K. Levanon, and R. Drapkin Modeling high-grade serous ovarian carcinogenesis from the fallopian tube Proc. Natl. Acad. Sci. U.S.A. 108 2011 7547 7552
105. J. Kim, D.M. Coffey, C.J. Creighton, Z. Yu, S.M. Hawkins, and M.M. Matzuk High-grade serous ovarian cancer arises from fallopian tube in a mouse model Proc. Natl. Acad. Sci. U.S.A. 109 2012 3921 3926
106. K.M. Kinross, K.G. Montgomery, M. Kleinschmidt, P. Waring, I. Ivetac, A. Tikoo, M. Saad, L. Hare, V. Roh, T. Mantamadiotis, K.E. Sheppard, G.L. Ryland, I.G. Campbell, K.L. Gorringe, J.G. Christensen, C. Cullinane, R.J. Hicks, R.B. Pearson, R.W. Johnstone, G.A. McArthur, and W.A. Phillips An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice J. Clin. Investig. 122 2012 553 557
107. G.J. Kitange, B.L. Carlson, M.A. Schroeder, P.T. Grogan, J.D. Lamont, P.A. Decker, W. Wu, C.D. James, and J.N. Sarkaria Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts Neuro-Oncology 11 2009 281 291
108. W. Kleine Prognostic significance of growth characteristics of xenotransplanted ovarian carcinomas into nude mice Gynecol. Oncol. 25 1986 65 72
109. R.A. Klinghoffer, S.B. Bahrami, B.A. Hatton, J.P. Frazier, A. Moreno-Gonzalez, A.D. Strand, W.S. Kerwin, J.R. Casalini, D.J. Thirstrup, S. You, S.M. Morris, K.L. Watts, M. Veiseh, M.O. Grenley, I. Tretyak, J. Dey, M. Carleton, E. Beirne, K.D. Pedro, S.H. Ditzler, E.J. Girard, T.L. Deckwerth, J.A. Bertout, K.A. Meleo, E.H. Filvaroff, R. Chopra, O.W. Press, and J.M. Olson A technology platform to assess multiple cancer agents simultaneously within a patient's tumor Sci. Transl. Med. 7 2015 284ra258
110. G.M. Kolfschoten, H.M. Pinedo, P.G. Scheffer, H.M. Schluper, C.A. Erkelens, and E. Boven Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system Gynecol. Oncol. 76 2000 362 368
111. G.E. Konecny, C. Wang, H. Hamidi, B. Winterhoff, K.R. Kalli, J. Dering, C. Ginther, H.W. Chen, S. Dowdy, W. Cliby, B. Gostout, K.C. Podratz, G. Keeney, H.J. Wang, L.C. Hartmann, D.J. Slamon, and E.L. Goode Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer J. Natl. Cancer Inst. 106 2014
112. P.A. Konstantinopoulos, and U.A. Matulonis Current status and evolution of preclinical drug development models of epithelial ovarian cancer Front. Oncol. 3 2013 296
113. P.A. Konstantinopoulos, D. Spentzos, B.Y. Karlan, T. Taniguchi, E. Fountzilas, N. Francoeur, D.A. Levine, and S.A. Cannistra Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer J. Clin. Oncol. 28 2010 3555 3561 (Official Journal of the American Society of Clinical Oncology)
114. M. Krajewska, R.S. Fehrmann, P.M. Schoonen, S. Labib, E.G. de Vries, L. Franke, and M.A. van Vugt ATR inhibition preferentially targets homologous recombination-deficient tumor cells Oncogene 34 2015 3474 3481
115. C. Kreuzinger, M. Gamperl, A. Wolf, G. Heinze, A. Geroldinger, D. Lambrechts, B. Boeckx, D. Smeets, R. Horvat, S. Aust, G. Hamilton, R. Zeillinger, and D. Cacsire Castillo-Tong Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer Cancer Lett. 362 2015 218 228
116. C.L. Krumdieck, J.E. dos Santos, and K.J. Ho A new instrument for the rapid preparation of tissue slices Anal. Biochem. 104 1980 118 123
117. J.D. Kuhlmann, P. Wimberger, A. Bankfalvi, T. Keller, S. Scholer, B. Aktas, P. Buderath, S. Hauch, F. Otterbach, R. Kimmig, and S. Kasimir-Bauer ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance Clin. Chem. 60 2014 1282 1289
118. R.J. Kurman, and M. Shih Ie The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am. J. Surg. Pathol. 34 2010 433 443
119. C.N. Landen Jr., M.J. Birrer, and A.K. Sood Early events in the pathogenesis of epithelial ovarian cancer J. Clin. Oncol. 26 2008 995 1005 (Official Journal of the American Society of Clinical Oncology)
120. S.P. Langdon, S.S. Lawrie, F.G. Hay, M.M. Hawkes, A. McDonald, I.P. Hayward, D.J. Schol, J. Hilgers, R.C. Leonard, and J.F. Smyth Characterization and properties of nine human ovarian adenocarcinoma cell lines Cancer Res. 48 1988 6166 6172
121. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, C.L. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, A. Fielding, S. Spencer, B. Dougherty, M. Orr, D. Hodgson, J.C. Barrett, and U. Matulonis Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 15 2014 852 861
122. C.H. Lee, H. Xue, M. Sutcliffe, P.W. Gout, D.G. Huntsman, D.M. Miller, C.B. Gilks, and Y.Z. Wang Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models Gynecol. Oncol. 96 2005 48 55
123. J.M. Lee, P. Mhawech-Fauceglia, N. Lee, L.C. Parsanian, Y.G. Lin, S.A. Gayther, and K. Lawrenson A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro Lab. Investig. 93 2013 528 542 (A Journal of Technical Methods and Pathology)
124. N. Leffers, M.J. Gooden, R.A. de Jong, B.N. Hoogeboom, K.A. ten Hoor, H. Hollema, H.M. Boezen, A.G. van der Zee, T. Daemen, and H.W. Nijman Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol. Immunother.: CII 58 2009 449 459
125. E. Lengyel, J.E. Burdette, H.A. Kenny, D. Matei, J. Pilrose, P. Haluska, K.P. Nephew, D.B. Hales, and M.S. Stack Epithelial ovarian cancer experimental models Oncogene 33 2014 3619 3633
126. I.J. Letourneau, M.C. Quinn, L.L. Wang, L. Portelance, K.Y. Caceres, L. Cyr, N. Delvoye, L. Meunier, M. de Ladurantaye, Z. Shen, S.L. Arcand, P.N. Tonin, D.M. Provencher, and A.M. Mes-Masson Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer BMC Cancer 12 2012 379
127. K. Levanon, V. Ng, H.Y. Piao, Y. Zhang, M.C. Chang, M.H. Roh, D.W. Kindelberger, M.S. Hirsch, C.P. Crum, J.A. Marto, and R. Drapkin Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis Oncogene 29 2010 1103 1113
128. S. Li, D. Shen, J. Shao, R. Crowder, W. Liu, A. Prat, X. He, S. Liu, J. Hoog, C. Lu, L. Ding, O.L. Griffith, C. Miller, D. Larson, R.S. Fulton, M. Harrison, T. Mooney, J.F. McMichael, J. Luo, Y. Tao, R. Goncalves, C. Schlosberg, J.F. Hiken, L. Saied, C. Sanchez, T. Giuntoli, C. Bumb, C. Cooper, R.T. Kitchens, A. Lin, C. Phommaly, S.R. Davies, J. Zhang, M.S. Kavuri, D. McEachern, Y.Y. Dong, C. Ma, T. Pluard, M. Naughton, R. Bose, R. Suresh, R. McDowell, L. Michel, R. Aft, W. Gillanders, K. DeSchryver, R.K. Wilson, S. Wang, G.B. Mills, A. Gonzalez-Angulo, J.R. Edwards, C. Maher, C.M. Perou, E.R. Mardis, and M.J. Ellis Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts Cell Rep. 4 2013 1116 1130
129. R. Lis, C. Touboul, C.M. Raynaud, J.A. Malek, K. Suhre, M. Mirshahi, and A. Rafii Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties PLoS ONE 7 2012 pe38340
130. J.F. Liu, D. Kindelberger, C. Doyle, A. Lowe, W.T. Barry, and U.A. Matulonis Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients Gynecol. Oncol. 131 2013 352 356
131. C.J. Lord, and A. Ashworth Mechanisms of resistance to therapies targeting BRCA-mutant cancers Nat. Med. 19 2013 1381 1388
132. S. Mahner, L. Woelber, V. Mueller, I. Witzel, K. Prieske, D. Grimm, V.A.G. Keller, and F. Trillsch Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer Front. Oncol. 5 2015 p211
133. D. Matei, F. Fang, C. Shen, J. Schilder, A. Arnold, Y. Zeng, W.A. Berry, T. Huang, and K.P. Nephew Epigenetic resensitization to platinum in ovarian cancer Cancer Res. 72 2012 2197 2205
134. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L. Clarke-Pearson, and M. Davidson Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Eng. J. Med. 334 1996 1 6
135. A. Meijer, F.A. Kruyt, A.G. van der Zee, H. Hollema, P. Le, K.A. ten Hoor, G.M. Groothuis, W.J. Quax, E.G. de Vries, and S. de Jong Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL Br. J. Cancer 109 2013 2685 2695
136. J.L. Meisel, D.M. Hyman, K. Garg, Q. Zhou, F. Dao, M. Bisogna, J. Gao, N.D. Schultz, R.N. Grisham, M. Phillips, A. Iasonos, N.D. Kauff, D.A. Levine, R.A. Soslow, and D.R. Spriggs The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer Ann. Oncol. 25 2014 2372 2378 (Official Journal of the European Society for Medical Oncology/ESMO)
137. R. Moser, C. Xu, M. Kao, J. Annis, L.A. Lerma, C.M. Schaupp, K.E. Gurley, I.S. Jang, A. Biktasova, W.G. Yarbrough, A.A. Margolin, C. Grandori, C.J. Kemp, and E. Mendez Functional kinomics identifies candidate therapeutic targets in head and neck cancer Clin. Cancer Res. 20 2014 4274 4288 (An Official Journal of the American Association for Cancer Research)
138. A. Mukhopadhyay, A. Elattar, A. Cerbinskaite, S.J. Wilkinson, Y. Drew, S. Kyle, G. Los, Z. Hostomsky, R.J. Edmondson, and N.J. Curtin Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors Clin. Cancer Res. 16 2010 2344 2351 (An Official Journal of the American Association for Cancer Research)
139. A. Mukhopadhyay, E.R. Plummer, A. Elattar, S. Soohoo, B. Uzir, J.E. Quinn, W.G. McCluggage, P. Maxwell, H. Aneke, N.J. Curtin, and R.J. Edmondson Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival Cancer Res. 72 2012 5675 5682
140. M. Murtaza, S.J. Dawson, D.W. Tsui, D. Gale, T. Forshew, A.M. Piskorz, C. Parkinson, S.F. Chin, Z. Kingsbury, A.S. Wong, F. Marass, S. Humphray, J. Hadfield, D. Bentley, T.M. Chin, J.D. Brenton, C. Caldas, and N. Rosenfeld Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Nature 497 2013 108 112
141. A.B. Nagaraj, P. Joseph, O. Kovalenko, S. Singh, A. Armstrong, R. Redline, K. Resnick, K. Zanotti, S. Waggoner, and A. DiFeo Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance Oncotarget 6 2015 23720 23734
142. C. Nardella, A. Lunardi, A. Patnaik, L.C. Cantley, and P.P. Pandolfi The APL paradigm and the "co-clinical trial" project Cancer Discov. 1 2011 108 116
143. K.M. Nieman, H.A. Kenny, C.V. Penicka, A. Ladanyi, R. Buell-Gutbrod, M.R. Zillhardt, I.L. Romero, M.S. Carey, G.B. Mills, G.S. Hotamisligil, S.D. Yamada, M.E. Peter, K. Gwin, and E. Lengyel Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth Nat. Med. 17 2011 1498 1503
144. B. Norquist, K.A. Wurz, C.C. Pennil, R. Garcia, J. Gross, W. Sakai, B.Y. Karlan, T. Taniguchi, and E.M. Swisher Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas J. Clin. Oncol. 29 2011 3008 3015 (Official Journal of the American Society of Clinical Oncology)
145. R.L. O'Donnell, A. McCormick, A. Mukhopadhyay, L.C. Woodhouse, M. Moat, A. Grundy, M. Dixon, A. Kaufman, S. Soohoo, A. Elattar, N.J. Curtin, and R.J. Edmondson The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis PLoS ONE 9 2014 pe90604
146. E. Obermayr, D.C. Castillo-Tong, D. Pils, P. Speiser, I. Braicu, T. Van Gorp, S. Mahner, J. Sehouli, I. Vergote, and R. Zeillinger Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the OVCAD consortium Gynecol. Oncol. 128 2013 15 21
147. S. Orsulic, Y. Li, R.A. Soslow, L.A. Vitale-Cross, J.S. Gutkind, and H.E. Varmus Induction of ovarian cancer by defined multiple genetic changes in a mouse model system Cancer Cell 1 2002 53 62
148. A.A. Osman, M.M. Monroe, M.V. Ortega Alves, A.A. Patel, P. Katsonis, A.L. Fitzgerald, D.M. Neskey, M.J. Frederick, S.H. Woo, C. Caulin, T.K. Hsu, T.O. McDonald, M. Kimmel, R.E. Meyn, O. Lichtarge, and J.N. Myers Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence Mol. Cancer Ther. 14 2015 608 619
149. V. Ouellet, M. Zietarska, L. Portelance, J. Lafontaine, J. Madore, M.L. Puiffe, S.L. Arcand, Z. Shen, J. Hebert, P.N. Tonin, D.M. Provencher, and A.M. Mes-Masson Characterization of three new serous epithelial ovarian cancer cell lines BMC Cancer 8 2008 p152
150. A.M. Oza, A.D. Cook, J. Pfisterer, A. Embleton, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, M.S. Carey, P. Beale, A. Cervantes, T.W. Park-Simon, G. Rustin, F. Joly, M.R. Mirza, M. Plante, M. Quinn, A. Poveda, G.C. Jayson, D. Stark, A.M. Swart, L. Farrelly, R. Kaplan, M.K. Parmar, T.J. Perren, and I.T. Investigators Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial Lancet Oncol. 16 2015 928 936
151. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, R.S. Mannel, K. DeGeest, E.M. Hartenbach, R. Baergen Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study J. Clin. Oncol. 21 2003 3194 3200 (Official Journal of the American Society of Clinical Oncology)
152. E. Pailler, J. Adam, A. Barthelemy, M. Oulhen, N. Auger, A. Valent, I. Borget, D. Planchard, M. Taylor, F. Andre, J.C. Soria, P. Vielh, B. Besse, and F. Farace Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer J. Clin. Oncol. 31 2013 2273 2281 (Official Journal of the American Society of Clinical Oncology)
153. M. Pajic, A. Kersbergen, F. van Diepen, A. Pfauth, J. Jonkers, P. Borst, and S. Rottenberg Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo Cell Cycle 9 2010 3780 3791
154. A.M. Patch, E.L. Christie, D. Etemadmoghadam, D.W. Garsed, J. George, S. Fereday, K. Nones, P. Cowin, K. Alsop, P.J. Bailey, K.S. Kassahn, F. Newell, M.C. Quinn, S. Kazakoff, K. Quek, C. Wilhelm-Benartzi, E. Curry, H.S. Leong, Australian Ovarian Cancer Study Group, A. Hamilton, L. Mileshkin, G. Au-Yeung, C. Kennedy, J. Hung, Y.E. Chiew, P. Harnett, M. Friedlander, M. Quinn, J. Pyman, S. Cordner, P. O'Brien, J. Leditschke, G. Young, K. Strachan, P. Waring, W. Azar, C. Mitchell, N. Traficante, J. Hendley, H. Thorne, M. Shackleton, D.K. Miller, G.M. Arnau, R.W. Tothill, T.P. Holloway, T. Semple, I. Harliwong, C. Nourse, E. Nourbakhsh, S. Manning, S. Idrisoglu, T.J. Bruxner, A.N. Christ, B. Poudel, O. Holmes, M. Anderson, C. Leonard, A. Lonie, N. Hall, S. Wood, D.F. Taylor, Q. Xu, J.L. Fink, N. Waddell, R. Drapkin, E. Stronach, H. Gabra, R. Brown, A. Jewell, S.H. Nagaraj, E. Markham, P.J. Wilson, J. Ellul, O. McNally, M.A. Doyle, R. Vedururu, C. Stewart, E. Lengyel, J.V. Pearson, N. Waddell, A. deFazio, S.M. Grimmond, and D.D. Bowtell Whole-genome characterization of chemoresistant ovarian cancer Nature 521 2015 489 494
155. C. Pisano, S. Greggi, R. Tambaro, S. Losito, F. Iodice, M. Di Maio, E. Ferrari, M. Falanga, R. Formato, V.R. Iaffaioli, and S. Pignata Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study Anticancer Res. 25 2005 3501 3505
156. A. Poveda, S.B. Kaye, R. McCormack, S. Wang, T. Parekh, D. Ricci, C.A. Lebedinsky, J.C. Tercero, P. Zintl, and B.J. Monk Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer Gynecol. Oncol. 122 2011 567 572
157. S. Pradeep, S.W. Kim, S.Y. Wu, M. Nishimura, P. Chaluvally-Raghavan, T. Miyake, C.V. Pecot, S.J. Kim, H.J. Choi, F.Z. Bischoff, J.A. Mayer, L. Huang, A.M. Nick, C.S. Hall, C. Rodriguez-Aguayo, B. Zand, H.J. Dalton, T. Arumugam, H.J. Lee, H.D. Han, M.S. Cho, R. Rupaimoole, L.S. Mangala, V. Sehgal, S.C. Oh, J. Liu, J.S. Lee, R.L. Coleman, P. Ram, G. Lopez-Berestein, I.J. Fidler, and A.K. Sood Hematogenous metastasis of ovarian cancer: rethinking mode of spread Cancer Cell 26 2014 77 91
158. S. Rottenberg, and P. Borst Drug resistance in the mouse cancer clinic Drug Resist. Updates 15 2012 81 89 (Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy)
159. S. Rottenberg, and J. Jonkers Modeling therapy resistance in genetically engineered mouse cancer models Drug Resist. Updates 11 2008 51 60 (Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy)
160. S. Rottenberg, A.O. Nygren, M. Pajic, F.W. van Leeuwen, I. van der Heijden, K. van de Wetering, X. Liu, K.E. de Visser, K.G. Gilhuijs, O. van Tellingen, J.P. Schouten, J. Jonkers, and P. Borst Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer Proc. Natl. Acad. Sci. U.S.A. 104 2007 12117 12122
161. I. Ruscito, D. Dimitrova, I. Vasconcelos, K. Gellhaus, T. Schwachula, F. Bellati, R. Zeillinger, P. Benedetti-Panici, I. Vergote, S. Mahner, D. Cacsire-Tong, N. Concin, S. Darb-Esfahani, S. Lambrechts, J. Sehouli, S. Olek, and E.I. Braicu BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD) Eur. J. Cancer 50 2014 2090 2098
162. R. Sabatier, P. Finetti, N. Cervera, D. Birnbaum, and F. Bertucci Gene expression profiling and prediction of clinical outcome in ovarian cancer Crit. Rev. Oncol./Hematol. 72 2009 98 109
163. W. Sakai, E.M. Swisher, B.Y. Karlan, M.K. Agarwal, J. Higgins, C. Friedman, E. Villegas, C. Jacquemont, D.J. Farrugia, F.J. Couch, N. Urban, and T. Taniguchi Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 2008 1116 1120
164. R.F. Schwarz, C.K. Ng, S.L. Cooke, S. Newman, J. Temple, A.M. Piskorz, D. Gale, K. Sayal, M. Murtaza, P.J. Baldwin, N. Rosenfeld, H.M. Earl, E. Sala, M. Jimenez-Linan, C.A. Parkinson, F. Markowetz, and J.D. Brenton Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis PLoS Med. 12 2015 pe1001789
165. C.L. Scott, M.A. Becker, P. Haluska, and G. Samimi Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment Front. Oncol. 3 2013 p295
166. M.M. Shah, Z.C. Dobbin, S. Nowsheen, M. Wielgos, A.A. Katre, R.D. Alvarez, P.A. Konstantinopoulos, E.S. Yang, and C.N. Landen An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer Gynecol. Oncol. 134 2014 331 337
167. R. Shakya, L.J. Reid, C.R. Reczek, F. Cole, D. Egli, C.S. Lin, D.G. deRooij, S. Hirsch, K. Ravi, J.B. Hicks, M. Szabolcs, M. Jasin, R. Baer, and T. Ludwig BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity Science 334 2011 525 528
168. D.W. Shen, L.M. Pouliot, M.D. Hall, and M.M. Gottesman Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes Pharmacol. Rev. 64 2012 706 721
169. M. Shih Ie, and R.J. Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am. J. Pathol. 164 2004 1511 1518
170. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics 2012 CA: Cancer J. Clin. 62 2012 10 29
171. G. Singer, R. Oldt.3rd., Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman, and IeM. Shih Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J. Natl. Cancer Inst. 95 2003 484 486
172. D. Siolas, and G.J. Hannon Patient-derived tumor xenografts: transforming clinical samples into mouse models Cancer Res. 73 2013 5315 5319
173. A. Sonnenblick, E. de Azambuja, H.A. Azim Jr., and M. Piccart An update on PARP inhibitors-moving to the adjuvant setting Nat. Rev. Clin. Oncol. 12 2015 27 41
174. D. Spentzos, D.A. Levine, M.F. Ramoni, M. Joseph, X. Gu, J. Boyd, T.A. Libermann, and S.A. Cannistra Gene expression signature with independent prognostic significance in epithelial ovarian cancer J. Clin. Oncol. 22 2004 4700 4710 (Official Journal of the American Society of Clinical Oncology)
175. C. Sun, N. Li, D. Ding, D. Weng, L. Meng, G. Chen, and D. Ma The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis PLoS ONE 9 2014 pe95285
176. E.M. Swisher, W. Sakai, B.Y. Karlan, K. Wurz, N. Urban, and T. Taniguchi Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance Cancer Res. 68 2008 2581 2586
177. L. Szabova, S. Bupp, M. Kamal, D.B. Householder, L. Hernandez, J.J. Schlomer, M.L. Baran, M. Yi, R.M. Stephens, C.M. Annunziata, P.L. Martin, T.A. Van Dyke, Z. Weaver Ohler, and S. Difilippantonio Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer PLoS ONE 9 2014 pe95649
178. L. Szabova, C. Yin, S. Bupp, T.M. Guerin, J.J. Schlomer, D.B. Householder, M.L. Baran, M. Yi, Y. Song, W. Sun, J.E. McDunn, P.L. Martin, T. Van Dyke, and S. Difilippantonio Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer Cancer Res. 72 2012 4141 4153
179. M.D. Topp, L. Hartley, M. Cook, V. Heong, E. Boehm, L. McShane, J. Pyman, O. McNally, S. Ananda, M. Harrell, D. Etemadmoghadam, L. Galletta, K. Alsop, G. Mitchell, S.B. Fox, J.B. Kerr, K.J. Hutt, S.H. Kaufmann, Australian Ovarian Cancer Study, E.M. Swisher, D.D. Bowtell, M.J. Wakefield, and C.L. Scott Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts Mol. Oncol. 8 2014 656 668
180. R.W. Tothill, A.V. Tinker, J. George, R. Brown, S.B. Fox, S. Lade, D.S. Johnson, M.K. Trivett, D. Etemadmoghadam, B. Locandro, N. Traficante, S. Fereday, J.A. Hung, Y.E. Chiew, I. Haviv, Australian Ovarian Cancer Study Group, D. Gertig, A. DeFazio, and D.D. Bowtell Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome Clin. Cancer Res. 14 2008 5198 5208 (An Official Journal of the American Association for Cancer Research)
181. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat. Rev. Cancer 4 2004 814 819
182. S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, G. Coukos, C.C. Crum, R. Drapkin, D. Etemadmoghadam, M. Friedlander, H. Gabra, S.B. Kaye, C.J. Lord, E. Lengyel, D.A. Levine, I.A. McNeish, U. Menon, G.B. Mills, K.P. Nephew, A.M. Oza, A.K. Sood, E.A. Stronach, H. Walczak, D.D. Bowtell, and F.R. Balkwill Rethinking ovarian cancer: recommendations for improving outcomes Nat. Rev. Cancer 11 2011 719 725
183. R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, S. Fereday, M. Lawrence, S.L. Carter, C.H. Mermel, A.D. Kostic, D. Etemadmoghadam, G. Saksena, K. Cibulskis, S. Duraisamy, K. Levanon, C. Sougnez, A. Tsherniak, S. Gomez, R. Onofrio, S. Gabriel, L. Chin, N. Zhang, P.T. Spellman, Y. Zhang, R. Akbani, K.A. Hoadley, A. Kahn, M. Kobel, D. Huntsman, R.A. Soslow, A. Defazio, M.J. Birrer, J.W. Gray, J.N. Weinstein, D.D. Bowtell, R. Drapkin, J.P. Mesirov, G. Getz, D.A. Levine, M. Meyerson Cancer Genome Atlas Research Network Prognostically relevant gene signatures of high-grade serous ovarian carcinoma J. Clin. Investig. 123 2013 517 525
184. A. Vidal, C. Munoz, M.J. Guillen, J. Moreto, S. Puertas, M. Martinez-Iniesta, A. Figueras, L. Padulles, F.J. Garcia-Rodriguez, M. Berdiel-Acer, M.A. Pujana, R. Salazar, M. Gil-Martin, L. Marti, J. Ponce, D.G. Mollevi, G. Capella, E. Condom, F. Vinals, D. Huertas, C. Cuevas, M. Esteller, P. Aviles, and A. Villanueva Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer Clin. Cancer Res. 18 2012 5399 5411 (An Official Journal of the American Association for Cancer Research)
185. Y. Wang, J. Waters, M.L. Leung, A. Unruh, W. Roh, X. Shi, K. Chen, P. Scheet, S. Vattathil, H. Liang, A. Multani, H. Zhang, R. Zhao, F. Michor, F. Meric-Bernstam, and N.E. Navin Clonal evolution in breast cancer revealed by single nucleus genome sequencing Nature 512 2014 155 160
186. S.J. Weroha, M.A. Becker, S. Enderica-Gonzalez, S.C. Harrington, A.L. Oberg, M.J. Maurer, S.E. Perkins, M. AlHilli, K.A. Butler, S. McKinstry, S. Fink, R.B. Jenkins, X. Hou, K.R. Kalli, K.M. Goodman, J.N. Sarkaria, B.Y. Karlan, A. Kumar, S.H. Kaufmann, L.C. Hartmann, and P. Haluska Tumorgrafts as in vivo surrogates for women with ovarian cancer Clin. Cancer Res. 20 2014 1288 1297 (An Official Journal of the American Association for Cancer Research)
187. K.C. Wiegand, S.P. Shah, O.M. Al-Agha, Y. Zhao, K. Tse, T. Zeng, J. Senz, M.K. McConechy, M.S. Anglesio, S.E. Kalloger, W. Yang, A. Heravi-Moussavi, R. Giuliany, C. Chow, J. Fee, A. Zayed, L. Prentice, N. Melnyk, G. Turashvili, A.D. Delaney, J. Madore, S. Yip, A.W. McPherson, G. Ha, L. Bell, S. Fereday, A. Tam, L. Galletta, P.N. Tonin, D. Provencher, D. Miller, S.J. Jones, R.A. Moore, G.B. Morin, A. Oloumi, N. Boyd, S.A. Aparicio, M. Shih Ie, A.M. Mes-Masson, D.D. Bowtell, M. Hirst, B. Gilks, M.A. Marra, and D.G. Huntsman ARID1A mutations in endometriosis-associated ovarian carcinomas N. Eng. J. Med. 363 2010 1532 1543
188. W.Z. Wysham, P. Mhawech-Fauceglia, H. Li, L. Hays, S. Syriac, T. Skrepnik, J. Wright, N. Pande, M. Hoatlin, and T. Pejovic BRCAness profile of sporadic ovarian cancer predicts disease recurrence PLoS ONE 7 2012 pe30042
189. D. Xing, and S. Orsulic A mouse model for the molecular characterization of brca1-associated ovarian carcinoma Cancer Res. 66 2006 8949 8953
190. G. Xu, F. Yin, H. Wu, X. Hu, L. Zheng, and J. Zhao In vitro ovarian cancer model based on three-dimensional agarose hydrogel J. Tissue Eng. 5 2014 2041731413520438
191. Y. Xu, D.F. Silver, N.P. Yang, E. Oflazoglu, R.E. Hempling, M.S. Piver, and E.A. Repasky Characterization of human ovarian carcinomas in a SCID mouse model Gynecol. Oncol. 72 1999 161 170
192. M. Yu, A. Bardia, N. Aceto, F. Bersani, M.W. Madden, M.C. Donaldson, R. Desai, H. Zhu, V. Comaills, Z. Zheng, B.S. Wittner, P. Stojanov, E. Brachtel, D. Sgroi, R. Kapur, T. Shioda, D.T. Ting, S. Ramaswamy, G. Getz, A.J. Iafrate, C. Benes, M. Toner, S. Maheswaran, and D.A. Haber Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility Science 345 2014 216 220
193. C. Zeller, W. Dai, N.L. Steele, A. Siddiq, A.J. Walley, C.S. Wilhelm-Benartzi, S. Rizzo, A. van der Zee, J.A. Plumb, and R. Brown Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling Oncogene 31 2012 4567 4576
194. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M.N. Liebman, S.C. Rubin, and G. Coukos Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N. Eng. J. Med. 348 2003 203 213
195. Q. Zhong, H.L. Peng, X. Zhao, L. Zhang, and W.T. Hwang Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis Clin. Cancer Res. 21 2015 211 220 (an official journal of the American Association for Cancer Research)